Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD138-interferon alpha2 fusion protein - Qwixel Therapeutics

Next Previous
Drug Profile

Anti-CD138-interferon alpha2 fusion protein - Qwixel Therapeutics

Alternative Names: CD138-targeted interferon - Qwixel Therapeutics

Latest Information Update: 25 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at Los Angeles
  • Developer Qwixel Therapeutics
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interferons; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Cell proliferation inhibitors; Interferon replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 02 Jun 2021 Preclinical trials in Multiple myeloma in USA (IV)
  • 06 Apr 2015 University of California has patent protection for anti-CD138-IFNa2 fusion protein in USA
  • 01 Apr 2015 Pharmacodynamics data from a preclinical studies in Multiple myeloma released by University of California

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top